Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 70   

Articles published

JNJ 102.26 +0.06 (0.06%)
price chart
Johnson & Johnson Names New Chairman
William C. Weldon, the chairman of Johnson & Johnson, is stepping down at the end of this year and will be succeeded by Alex Gorsky, the current chief executive, the company announced Friday.
Johnson & Johnson Elects CEO Gorsky Chairman  Fox Business
Weldon passes baton at Johnson & Johnson to Gorsky
Related articles »  
Johnson & Johnson's Go-To Business Schools
The following table shows the top schools for Johnson & Johnson (JNJ). J&J hired only 83 2012 MBA grads from the schools in our sample, making it the 13th biggest MBA employer, well behind such giants in MBA recruiting as McKinsey, Boston Consulting ...
Dr. Buffett Has Diagnosed Johnson & Johnson As Too Big To Succeed
We are amazed that Johnson & Johnson's (NYSE:JNJ) shares have held up better than the S&P 500 over the last month.
Johnson & Johnson, Merck and Eli Lilly to rip red tape from clinical trials
Johnson & Johnson's ($JNJ) Janssen R&D unit is leading a charge to expedite the tedious process of selecting sites for clinical trial sites, with the creation of a investigator database intended to get studies up and running more efficiently.
J&J, Lilly, Merck plan clinical trial site database  Reuters
Janssen Forms �Investigator Databank� to Help Streamline Drug Trials  Xconomy
Related articles »  
J&J says it won't enforce AIDS drug patent in Africa
LONDON (Reuters) - Generic manufacturers are to be given a free rein to make cheap copies of Johnson & Johnson's HIV/AIDS drug Prezista for sale in Africa and other poor countries.
J&J Won't Enforce Patents on HIV Medicine in Africa  Businessweek
Related articles »  
Johnson & Johnson One-Ups Tuberculosis
In an 18-0 ruling on efficacy, the FDA advisory committee voted in favor of Johnson & Johnson's bedaquiline, a drug to combat multidrug-resistant tuberculosis.
FDA panel says novel TB drug is safe  Vaccine News Daily (blog)
Related articles »  
Amgen, Johnson & Johnson, Bernstein Litowitz, and the fraud on the market theory
You might remember that the Center for Class Action Fairness objected to a $0 settlement in Johnson & Johnson. The objector argued that the settlement provided no benefit to shareholders.
Insurance And Income: Protecting Johnson & Johnson
In our previous article we discussed our observations about the difficulties insuring stock positions that pay a high dividend yield.
Johnson & Johnson Campaign for Nursings Future turns 10
Ten years ago a nursing shortage loomed in the United States. A shortfall of about 400,000 nurses by 2020 was projected and, between 1983 and 1998, the proportion of RNs younger than 30 had dropped from 30% to 12%, according to a 2000 article in the ...
Related articles »  
Buy Johnson & Johnson For Rock Solid Dividends - No Capital Appreciation ...
Johnson & Johnson (NYSE:JNJ) operates under three segments: Pharmaceutical (eighth largest in the world), Medical Devices and Diagnostic (the largest in the world) and Consumer (6th largest in the world).